AlphAIAlphAI — Financial news for AI agents
investing.comOCT 272 min read$IQV

IQVIA Q3 2026 slides: double-digit EPS growth, raised outlook

IQVIA Holdings reported Q3 2026 results with adjusted EPS of $3.34, up 11.3% YoY, and revenue of $4.43B, up 8.0%. The company raised its full-year outlook, citing strong organic growth and demand. Shares traded near their 52-week high at $274.92. CEO Ari Bousbib highlighted acceleration in growth rates and AI investments.

Original reporting
investing.com
Published Oct 27, 2026, 2:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IQV
Bullish
high confidence
Mentioned
$IQV
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IQVBullishHigh
01

Why it matters

The earnings beat and raised outlook suggest continued growth in outsourced clinical and commercial services, potentially attracting new contracts.

02

Market read

First‑report earnings and guidance raise for a large‑cap health‑tech firm, likely to move the stock and sector.

03

What to watch

High net debt and leverage ratios may limit upside if macro conditions tighten.

Relevance 9/10Novelty 9/10Timing: after‑hours release on Oct 27

Background

IQVIA is a leading provider of data, technology, and services to the life‑sciences industry.

Company-level read

Ticker impact

$IQVBullishHigh confidence
Context

IQVIA reported Q3 2026 results with 11.3% EPS growth and raised full-year guidance to $12.90‑$13.00 EPS.

Expected impact

upward pressure as investors price in higher earnings outlook

Evidence & confidence

The earnings beat and guidance increase are primary disclosures for a large‑cap health‑tech firm, providing fresh material for trading decisions.

Market effects

Sector

Strong results may boost the broader life‑sciences outsourcing sector as demand for contract research rises.

Regional

Positive for U.S. healthcare services equities and could lift related ETFs.

Global

Reinforces global biotech funding trends, supporting international CRO partners.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, any miss on Q4 could trigger a sharp correction.

Key entities

  • CEO
    Ari Bousbib

    IQVIA Chief Executive who highlighted AI strategy and growth.

Read at source← All news

StoryIQVIA reports Q3 2026 beat and lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

OCT 28
$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.

fool.com2 min
OCT 27
$IQVHighAI 8/10

IQVIA Holdings Inc. Q3 2026 Earnings Call Summary

IQVIA Holdings Inc. reported Q3 2026 organic revenue growth of 6%, driven by clinical segment momentum and AI integration. The Emerging Biopharma segment saw record demand with $90B funding YTD. Full-year guidance was raised, with AI expected to support future margin expansion. Management highlighted competitive advantages through AI and strategic partnerships. Q4 interest expense is projected at $210M. A $2.1B backlog scrub was conducted to improve visibility.

finance.yahoo.com3 min